Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
NEWARK, Calif., March 06, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that senior management will present at the following healthcare conferences during the month of March.
29th Annual ROTH Conference
Date: Monday, March 13, 2017
Time: 3:00 p.m. PDT
Location: Dana Point, CaliforniaOppenheimer 27th Annual Healthcare Conference
Date: Tuesday, March 21, 2017
Time: 8:30 a.m. EDT
Location: New York, New York
These presentations will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
